Catabasis pharmaceuticals inc (CATB)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Revenue

-

-

500

-

-

-

-

Operating expenses:
Research and development

18,317

17,042

18,682

25,450

23,030

15,686

13,994

General and administrative

8,771

9,329

8,912

10,108

8,629

5,995

4,125

Total operating expenses

27,088

26,371

27,594

35,558

31,659

21,681

18,119

Loss from operations

-27,088

-26,371

-27,094

-35,558

-31,659

-21,681

-18,119

Other income (expense):
Interest expense

-

100

-

-

-

-

-

Interest expense

-

-

462

837

978

206

-

Interest and investment income

845

425

160

242

-

-

-

Other (expense) income, net

-50

176

32

93

7

3

1

Total other income, net

795

501

-270

-502

-971

-203

1

Net loss

-26,293

-25,870

-27,364

-36,060

-32,630

-21,884

-18,118

Net loss per share - basic and diluted (in dollars per share)

-2.35

-5.12

-12.62

-2.22

-4.06

-51.56

-47.80

Weighted-average common shares outstanding used in net loss per share - basic and diluted (in shares)

11,199

5,054

2,168

16,230

8,041

424

379